bafetinib

(redirected from INNO-406)

bafetinib

A Bcr-Abl/Lyn dual tyrosine kinase inhibitor, which may suppress the growth of CLL cells by inhibition of Lyn kinase. Imatinib-resistant CLL cells are associated with an overexpression of Lyn kinase, a factor in the proliferation and survival of B-CLL cells. It has no effect on c-Src kinase activity, and may be less toxic than other broad Src family kinase inhibitors. Bafetinib has shown therapeutic potential in phase-II trials in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
15 January 2010 - US-based biopharmaceutical company CytRx Corporation (NASDAQ:CYTR) said on Wednesday it plans to initiate a Phase II proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib (formerly known as INNO-406) in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).